Cencora stock: Baird raises target to USD 375 for Cencora stock

Published on 10/23/2026 at 16:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal third-quarter revenue reached USD 84.80 billion, with USD 4.48 adjusted EPS. Cencora stock costs EUR 299.40 on October 23, 2026.

Analyst target and reporting date

Baird raised its Cencora target from USD 373.00 to USD 375.00 on October 22, 2026.
Fiscal third-quarter revenue reached USD 84.80 billion, with adjusted earnings per share of USD 4.48.
Cencora stock costs EUR 299.40 at Lang & Schwarz on October 23, 2026 at 4:32 p.m. CEST.
Cencora's next earnings release is scheduled for November 4, 2026.

Luftbild eines modernen Pharma-Lagerzentrums mit Lieferfahrzeugen und Verladedocks — Cencora Inc. betreibt US15135B1017 ein großes Pharmadistributionszentrum mit Lastwagen Gabelstaplern und täglicher Medikamentenlogistik, Illustration mit AI erstellt.

Cencora Inc. stock has a fresh analyst reference point after Markets Insider reported on October 22, 2026 that Baird raised its price target from USD 373.00 to USD 375.00 and maintained an Outperform rating. Cencora stock was trading at EUR 299.40 at Lang & Schwarz on October 23, 2026 at 4:32 p.m. CEST.

Revenue reached USD 84.80 billion

The latest reported operating picture is substantial. Investing.com said Cencora posted fiscal third-quarter 2026 revenue of USD 84.80 billion and adjusted earnings per share of USD 4.48. Revenue increased 5.00 percent from the prior year, while adjusted operating income rose 17.00 percent, giving the analyst target its operating backdrop.

Stock sits below its yearly high

On the NYSE, Cencora was trading at USD 335.29 on October 23, 2026 at 10:37 a.m. ET. The session range was USD 334.00 to USD 338.07, while the 52-week range was USD 244.82 to USD 377.54. The market capitalization was USD 64.0 billion, and the price-to-earnings ratio was 24.89.

November 4 sets the next date

MarketScreener lists November 4, 2026 as Cencora's next earnings release date. In a separate October 22 update, Markets Insider reported that BofA raised its target from USD 330.00 to USD 345.00 while keeping a Neutral rating. That target is below Baird's USD 375.00 view, illustrating a wider range of analyst expectations.

Comparison with peers

Cencora Inc.: price-to-earnings ratio 24.89, market capitalization USD 64.0 billion. McKesson Corporation: down 0.44 percent, price-to-earnings ratio 26.97, market capitalization USD 117.5 billion. Cardinal Health: down 0.98 percent, price-to-earnings ratio 35.03, market capitalization USD 58.6 billion.

Analyst support meets a clear date

Baird's USD 375.00 target and the November 4 earnings date give investors two concrete reference points. The latest quarterly figures also show the scale of Cencora's distribution business, while the USD 334.00 to USD 338.07 session range places the NYSE quote in a narrow daily band.

The stock was trading at EUR 299.40 at Lang & Schwarz on October 23, 2026 at 4:32 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Cencora stock.